Scholarlink

Background <p>Pomaglumetad methionil (LY2140023 monohydrate) is a potent and selective agonist for metabotropic glutamate receptors (mGluR2/3). Unlike traditional antipsychotics, it does not directly interact with dopamine or serotonin (5-HT2A) receptors, potentially offering a novel mechanism of action with a different side-effect profile. We aim to provide an overview of this novel drug and evaluate its efficacy in comparison to both placebo and atypical antipsychotics by performing a systematic review and meta-analysis.</p> Methods <p>A comprehensive literature search was conducted to identify relevant studies. The included studies investigated the effect of Promogulated methionil. The quality of studies was assessed using the Cochrane Risk of Bias 2 (ROB-2) Statistical analysis was conducted using Review Manager (revman) with outcomes expressed as Mean differences (MD) with 95% confidence intervals (CI).</p> Results <p>The systematic review included 4 randomized clinical trials (RCTs). The analysis revealed that pomaglumetad methionil (LY2140023) didn’t have a statistically significant effect on PANNS compared to placebo (p-value = 0.31) and it was less effective in decreasing PANSS score in comparison to atypical antipsychotics (p-value &lt; 0.00001). However, the drug showed a significant effect on weight gain (p-value &lt; 0.00001) and prolactin (<i>p</i> &lt; 0.0001) in comparison to atypical antipsychotics.</p> Conclusions <p>In conclusion, this systematic review and meta-analysis provide evidence that pomaglumetad methionil (LY2140023) does not demonstrate consistent efficacy in the treatment of schizophrenia. Although the compound is associated with a more favorable profile regarding weight gain and prolactin elevation, these advantages do not compensate for its lack of therapeutic efficacy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pomgulated methionil (LY2140023) in schizophrenia patients: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月8日

查看全文
  • Hala Aboushawareb,
  • Omar F. Abbas,
  • Hend Ghabour,
  • Omar Hassan,
  • Ali Nagy Shelbaya,
  • Rahma Abdelsalam,
  • Mostafa Meshref

摘要

Background

Pomaglumetad methionil (LY2140023 monohydrate) is a potent and selective agonist for metabotropic glutamate receptors (mGluR2/3). Unlike traditional antipsychotics, it does not directly interact with dopamine or serotonin (5-HT2A) receptors, potentially offering a novel mechanism of action with a different side-effect profile. We aim to provide an overview of this novel drug and evaluate its efficacy in comparison to both placebo and atypical antipsychotics by performing a systematic review and meta-analysis.

Methods

A comprehensive literature search was conducted to identify relevant studies. The included studies investigated the effect of Promogulated methionil. The quality of studies was assessed using the Cochrane Risk of Bias 2 (ROB-2) Statistical analysis was conducted using Review Manager (revman) with outcomes expressed as Mean differences (MD) with 95% confidence intervals (CI).

Results

The systematic review included 4 randomized clinical trials (RCTs). The analysis revealed that pomaglumetad methionil (LY2140023) didn’t have a statistically significant effect on PANNS compared to placebo (p-value = 0.31) and it was less effective in decreasing PANSS score in comparison to atypical antipsychotics (p-value < 0.00001). However, the drug showed a significant effect on weight gain (p-value < 0.00001) and prolactin (p < 0.0001) in comparison to atypical antipsychotics.

Conclusions

In conclusion, this systematic review and meta-analysis provide evidence that pomaglumetad methionil (LY2140023) does not demonstrate consistent efficacy in the treatment of schizophrenia. Although the compound is associated with a more favorable profile regarding weight gain and prolactin elevation, these advantages do not compensate for its lack of therapeutic efficacy.